AZN:LON
AstraZeneca PLC (US)
GBX 12,700.00
arrow_upward
+1.67%(+208.00) 1D
Sep 29, 6:21:42 PM GMT+1 · GBX
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
GBX 12,526.00
High
GBX 12,788.00
Low
GBX 12,386.00
Mkt. cap
253.75B
Avg. vol.
2.80M
Volume
2.70M
Dividend
1.88%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
25.16
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.05
Shares outstanding
1.55B
No. of employees
96K
Open
GBX 12,526.00
High
GBX 12,788.00
Low
GBX 12,386.00
Mkt. cap
253.75B
Avg. vol.
2.80M
Volume
2.70M
Dividend
1.88%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
25.16
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.05
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
This is Money
·
2 hours ago
AstraZeneca takes a £1.5bn stake in US cancer drug developer as it steps up investment in America
www.marketscreener.com
·
4 hours ago
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
StocksToTrade
·
4 hours ago
SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet
TradingView
·
6 hours ago
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com